Abstract
Purpose
Previous studies have suggested the potential prognostic value of circulating tumor cells (CTCs) in bladder cancer (BC) patients. This study aims to validate the prognostic value of in vivo detection of CTCs in muscle invasive bladder cancer (MIBC) patients receiving neoadjuvant chemotherapy (NAC).
Methods
A total of 107 MIBC patients were enrolled in this study. All patients had one in vivo detection of CTCs before initial treatment as baseline, and those who received neoadjuvant chemotherapy (NAC) had a second detection after NAC and before radical cystectomy. CTCs dynamic change after NAC was analyzed. Prognostic value of in vivo CTCs detection was investigated.
Results
Among 68 patients who received NAC, 45 patients (66%) had a CTC reduction after NAC. CTC reduction instead of baseline CTC positivity was a key prognostic factor for better progression free survival (PFS) among all MIBC patients receiving NAC in Kaplan–Meier analysis (P < 0.01) and in both crude (HR 6.14, 95%CI 1.63–23.21) and adjusted regression model (HR 6.76, 95% CI 1.59–28.88). The AUC was 0.85.
Conclusion
Our study demonstrated the prognostic value of in vivo detection of CTCs. The dynamic change of CTCs count may help evaluate the efficacy of NAC.
Similar content being viewed by others
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
References
R.L. Siegel, K.D. Miller, H.E. Fuchs, A. Jemal, CA Cancer J Clin 72, 7–33 (2022). https://doi.org/10.3322/caac.21708
A.T. Lenis, P.M. Lec, K. Chamie, M.D. Mshs, JAMA 324, 1980–1991 (2020). https://doi.org/10.1001/jama.2020.17598
J.A. Witjes, H.M. Bruins, R. Cathomas, E.M. Comperat, N.C. Cowan, G. Gakis, V. Hernandez, E. Linares Espinos, A. Lorch, Y. Neuzillet, M. Rouanne, G.N. Thalmann, E. Veskimae, M.J. Ribal, A.G. van der Heijden, Eur. Urol. 79, 82–104 (2021). https://doi.org/10.1016/j.eururo.2020.03.055
International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, the Australian Bladder Cancer Study Group, the National Cancer Institute of Canada Clinical Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group, and Club Urologico Espanol de Tratamiento Oncologico Group, J. Clin. Oncol. 29, 2171–2177 (2011). https://doi.org/10.1200/JCO.2010.32.3139
A.C. Small, Y. Gong, W.K. Oh, S.J. Hall, C.J. van Rijn, M.D. Galsky, J. Urol. 188, 21–26 (2012). https://doi.org/10.1016/j.juro.2012.02.2558
H. Jiang, X. Gu, Z. Zuo, G. Tian, J. Liu, PLoS One 16, e0254433 (2021). https://doi.org/10.1371/journal.pone.0254433
B. Hong, Y. Zu, Theranostics 3, 377–394 (2013). https://doi.org/10.7150/thno.5195
O. Vermesh, A. Aalipour, T.J. Ge, Y. Saenz, Y. Guo, I.S. Alam, S.M. Park, C.N. Adelson, Y. Mitsutake, J. Vilches-Moure, E. Godoy, M.H. Bachmann, C.C. Ooi, J.K. Lyons, K. Mueller, H. Arami, A. Green, E.I. Solomon, S.X. Wang, S.S. Gambhir, Nat. Biomed. Eng. 2, 696–705 (2018). https://doi.org/10.1038/s41551-018-0257-3
J. Budna-Tukan, M. Swierczewska, M. Mazel, W.A. Cieslikowski, A. Ida, A. Jankowiak, A. Antczak, M. Nowicki, K. Pantel, D. Azria, M. Zabel, C. Alix-Panabieres, Cancers (Basel) 11, (2019). https://doi.org/10.3390/cancers11060802
S. Chen, G. Tauber, T. Langsenlehner, L.M. Schmolzer, M. Potscher, S. Riethdorf, A. Kuske, G. Leitinger, K. Kashofer, Z.T. Czyz, B. Polzer, K. Pantel, P. Sedlmayr, T. Kroneis, A. El-Heliebi, Cancers (Basel) 11, (2019). https://doi.org/10.3390/cancers11070933
E.P. Darga, E.M. Dolce, F. Fang, K.M. Kidwell, C.L. Gersch, S. Kregel, D.G. Thomas, A. Gill, M.E. Brown, S. Gross, M. Connelly, M. Holinstat, E.F. Cobain, J.M. Rae, D.F. Hayes, C. Paoletti, PLoS One 16, e0260124 (2021). https://doi.org/10.1371/journal.pone.0260124
S.J. Cohen, C.J. Punt, N. Iannotti, B.H. Saidman, K.D. Sabbath, N.Y. Gabrail, J. Picus, M.A. Morse, E. Mitchell, M.C. Miller, G.V. Doyle, H. Tissing, L.W. Terstappen, N.J. Meropol, Ann. Oncol. 20, 1223–1229 (2009). https://doi.org/10.1093/annonc/mdn786
Y. Han, D. Liu, L. Li, Am. J. Cancer Res. 10, 727–742 (2020)
J. Abrahamsson, K. Aaltonen, H. Engilbertsson, F. Liedberg, O. Patschan, L. Ryden, G. Sjodahl, S. Gudjonsson, Urol. Oncol. 35, 606.e609-606.e616 (2017). https://doi.org/10.1016/j.urolonc.2017.05.021
P. Gazzaniga, E. de Berardinis, C. Raimondi, A. Gradilone, G.M. Busetto, E. De Falco, C. Nicolazzo, R. Giovannone, V. Gentile, E. Cortesi, K. Pantel, Int. J. Cancer 135, 1978–1982 (2014). https://doi.org/10.1002/ijc.28830
M. Rink, F.K. Chun, R. Dahlem, A. Soave, S. Minner, J. Hansen, M. Stoupiec, C. Coith, L.A. Kluth, S.A. Ahyai, M.G. Friedrich, S.F. Shariat, M. Fisch, K. Pantel, S. Riethdorf, Eur. Urol. 61, 810–817 (2012). https://doi.org/10.1016/j.eururo.2012.01.017
M. Rink, F.K. Chun, S. Minner, M. Friedrich, O. Mauermann, H. Heinzer, H. Huland, M. Fisch, K. Pantel, S. Riethdorf, BJU Int. 107, 1668–1675 (2011). https://doi.org/10.1111/j.1464-410X.2010.09562.x
A. Soave, S. Riethdorf, R. Dahlem, S. Minner, L. Weisbach, O. Engel, M. Fisch, K. Pantel, M. Rink, BJU Int. 119, 854–861 (2017). https://doi.org/10.1111/bju.13782
A. Zapatero, A. Gomez-Caamano, M.A. Cabeza Rodriguez, L. Muinelo-Romay, C. Martin de Vidales, A. Abalo, P. Calvo Crespo, L. Leon Mateos, C. Olivier, and L.V. Vega Piris, Radiat Oncol 15, 137 (2020). https://doi.org/10.1186/s13014-020-01577-5
H.L. Wang, J.Q. Wu, Y. Wang, J. Yu, X.N. Mao, Z.R. Li, H.R. Niu, C.L. Jin, X.J. Wang, Z.H. Yan, L. Yi, B. Yang, P.J. Wei, H.T. Zhang, S.C. Zhang, Neoplasma 68, 823–831 (2021). https://doi.org/10.4149/neo_2021_210115N67
A. Alva, T. Friedlander, M. Clark, T. Huebner, S. Daignault, M. Hussain, C. Lee, K. Hafez, B. Hollenbeck, A. Weizer, G. Premasekharan, T. Tran, C. Fu, C. Ionescu-Zanetti, M. Schwartz, A. Fan, P. Paris, J. Urol. 194, 790–798 (2015). https://doi.org/10.1016/j.juro.2015.02.2951
W.T. Yan, X. Cui, Q. Chen, Y.F. Li, Y.H. Cui, Y. Wang, J. Jiang, Sci. Rep. 7, 43464 (2017). https://doi.org/10.1038/srep43464
D. Olmos, H.T. Arkenau, J.E. Ang, I. Ledaki, G. Attard, C.P. Carden, A.H. Reid, R. A’Hern, P.C. Fong, N.B. Oomen, R. Molife, D. Dearnaley, C. Parker, L.W. Terstappen, J.S. de Bono, Ann. Oncol. 20, 27–33 (2009). https://doi.org/10.1093/annonc/mdn544
T. Jiang, J. Zhao, C. Zhao, X. Li, J. Shen, J. Zhou, S. Ren, C. Su, C. Zhou and M. O’Brien, Clin Lung Cancer 20, 124–133 e122 (2019). https://doi.org/10.1016/j.cllc.2018.11.014
L. Dizdar, G. Fluegen, G. van Dalum, E. Honisch, R.P. Neves, D. Niederacher, H. Neubauer, T. Fehm, A. Rehders, A. Krieg, W.T. Knoefel, N.H. Stoecklein, Mol. Oncol. 13, 1548–1558 (2019). https://doi.org/10.1002/1878-0261.12507
Funding
This work was supported by the National Natural Science Foundation of China (82173076, 82103485), Shanghai Natural Science Foundation (20Y11904900), Young Talent Project in Healthcare of Shanghai Municipal Health Commission (2022YQ014), Shanghai Hospital Development Center (SHDC2022CRD034) and Innovative Research Team of High-level Local Universities in Shanghai.
Author information
Authors and Affiliations
Contributions
Di Jin, Liang Dong, and Haige Chen designed studies, analyzed, and wrote the manuscript. Di Jin, Lei Qian, Jun Xia, and Ming Cao conducted the experiments and data analysis. Guoliang Yang, Ruiyun Zhang, Lianhua Zhang and Wei Xue collected the patient samples, follow-up information, and performed the clinical data analysis. Lei Qian and Liang Dong prepared figures and table. All authors reviewed and approved the final manuscript.
Corresponding authors
Ethics declarations
Ethical approval
The study complies with the Declaration of Helsinki and was conducted following the approval from Renji Hospital Ethics Committee. Written informed consent was obtained from all the patients.
Competing interests
The authors have no competing interests to declare that are relevant to the content of this article.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Jin, D., Qian, L., Xia, J. et al. In vivo detection demonstrates circulating tumor cell reduction instead of baseline number has prognostic value in bladder cancer patients receiving neoadjuvant chemotherapy. Cell Oncol. 46, 793–797 (2023). https://doi.org/10.1007/s13402-023-00785-x
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13402-023-00785-x